Travere Therapeutics (TVTX) Total Current Liabilities (2012 - 2026)

Travere Therapeutics' Total Current Liabilities history runs 15 years deep, the most recent figure standing at $125.4 million for Q1 2026.

• Quarterly Total Current Liabilities fell 31.25% year-over-year to $125.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $125.4 million (down 31.25% YoY) and the FY2025 annual result came in at $159.9 million, down 20.35% from the prior year.
• Total Current Liabilities was $125.4 million for Q1 2026 at Travere Therapeutics, down from $159.9 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $200.8 million in Q4 2024 and bottomed at $119.5 million in Q1 2022.
• A 5-year average of $151.7 million and a median of $139.4 million in 2023 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2025 — Total Current Liabilities jumped 56.3% — and 2026, when it sank 31.25%.
• Travere Therapeutics' Total Current Liabilities stood at $142.2 million in 2022, then increased by 25.14% to $177.9 million in 2023, then climbed by 12.84% to $200.8 million in 2024, then fell by 20.35% to $159.9 million in 2025, then fell by 21.55% to $125.4 million in 2026.
• Business Quant data shows TVTX's Total Current Liabilities at $125.4 million in Q1 2026, $159.9 million in Q4 2025, and $135.1 million in Q3 2025.